Press Releases

Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer

October 29, 2015:

Nymox Pharmaceutical Corporation reported today that long-term randomized cross-over data from the Companys trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.


Nymox Announces Change of Company’s Domicile and Head Office

August 4, 2015:

Nymox Pharmaceutical Corporation is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.


Nymox Announces Appointment of James G. Robinson to Board of Directors

July 30, 2015:

Nymox Pharmaceutical Corporation is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.


Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online

July 28, 2015:

(July 28, 2015) Nymox’s (NASDAQ:NYMX) July 27th webcast of news and
discussion by experts of the Company’s new clinical trial results can be viewed at
http://limelightdc.com/clientarea/nymox_investor_webcast_7_15/player_vod.html. The link is also available at
the Company’s website.


Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207).

July 27, 2015:

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Companys U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.


Nymox Appoints Cutler & Co. as Auditor

July 16, 2015:

July 16, 2015: On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company’s new independent registered public accounting firm to replace KPMGLLP.


Nymox Announces Appointment of Erik Danielsen as CFO

July 13, 2015:

Nymox Pharmaceutical Corporation is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company.


Nymox Announces $850,000 Financing

June 16, 2015:

Nymox Pharmaceutical Corporation is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66.


Nymox Reports First Quarter 2015 Financial Results

May 15, 2015:

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.


Nymox Announces New Prostate Cancer Clinical Trial Results

April 20, 2015:

Nymox Pharmaceutical Corporation announced today long-term clinical trial results from the Companys NX-1207 prostate cancer study NX03-0040.